問卷
Log In
繁中 EN
TPIDB
TPIDB Outstanding PI
TPIDB > Principal Investigator

Principal Investigator


China Medical University Hospital (在職)

Division of General Internal Medicine

Digestive System Department

Division of Hematology & Oncology

更新時間：2023-09-19

王鴻偉Wang, Hung-Wei
  • Principal Investigator
  • Clinical Trial Experience (year) 12 years 9 個月

  • D29280@mail.cmuh.org.tw

Recruiting Trial

44Cases

篩選

Developmental Phase

  • Phase I

  • Phase I/II

  • Phase II

  • Phase II/III

  • Phase III

  • Phase IV

  • Others

Trial Status

  • Not yet recruiting

  • Active

  • Completed

Recruitment Status

  • Not yet recruiting

  • Recruiting

  • Completed

  • Terminated

  • Stop recruiting

  • Suspended

  • Study ended

Trial scale

  • Multi-Regional Multi-Center

  • Taiwan Multiple Center

  • Taiwan Single Center

The expected start time interval of the test

-

Trial Applicant

  • Hospital/Foundation

  • Pharmaceutical/Biopharmaceutical company

  • Contract Research Organization

Important Roles

  • Asia Regional PI

  • Taiwan National PI

  • Chairman/Global PI

  • Steering Committee

  • Advisory board

  • None

Audit by Sponsors/CRO

  • Sponsors

  • CRO

  • None

Investigator-initiated trial(IIT)

  • Yes

Filters

王鴻偉

List

65Cases

2021-01-04 - 2025-12-31

IIT

Others

Active
An open-label, multicenter, randomized, active control study, comparing P1101 monotherapy to entecavir monotherapy in patients with HBeAg-negative chronic hepatitis B under long-term nucleos(t)ide analogue therapy

  • Condition/Disease

    chronic hepatitis B virus infection

  • Test Drug

    Ropeginterferon alfa-2b (P1101)

Participate Sites
6Sites

Not yet recruiting1Sites

Recruiting5Sites

2023-09-01 - 2027-12-31

Phase III

Active
A Phase III, Randomized, Double-Blind, Placebo-Controlled Study Evaluating Atezolizumab and Bevacizumab, With or Without Tiragolumab, in Patients With Untreated Locally Advanced or Metastatic Hepatocellular Carcinoma

  • Condition/Disease

    Carcinoma, Hepatocellular

  • Test Drug

    AtezolizumabBevacizumabTiragolumab

Participate Sites
5Sites

Recruiting5Sites

2022-07-01 - 2027-02-26

Phase II

Active

  • Condition/Disease

  • Test Drug

Participate Sites
8Sites

Not yet recruiting4Sites

Recruiting4Sites

2025-02-03 - 2029-12-23

Phase III

Not yet recruiting
A Phase 3 Randomized, Double-Blind, Placebo-Controlled Study of TPST-1120 in Combination with Atezolizumab plus Bevacizumab Compared with Placebo plus Atezolizumab plus Bevacizumab in Patients with Unresectable or Metastatic Hepatocellular Carcinoma (HCC) Not Previously Treated with Systemic Therapy

  • Condition/Disease

    HCC

  • Test Drug

    TPST-1120

Participate Sites
6Sites

Recruiting6Sites

2020-10-01 - 2025-12-31

Phase II

Completed
A Phase 2, Multicenter, Randomized, Double-blind, Placebo‑controlled Study with Deferred Active Treatment to Investigate the Efficacy, Safety, and Pharmacokinetics of JNJ‑73763989 + Nucleos(t)ide Analog in Participants Co‑infected with Hepatitis B and Hepatitis D Virus

  • Condition/Disease

    Patients infected with both hepatitis B and D viruses

  • Test Drug

    JNJ-73763989

Participate Sites
3Sites

Recruiting3Sites

2021-01-18 - 2023-08-31

Phase II

Completed
A Phase 2, Open-label, Single-arm, Multicenter Study to Assess Efficacy, Safety, Tolerability, and Pharmacokinetics of Treatment With JNJ-73763989, JNJ-56136379, Nucleos(t)ide Analogs, and Pegylated Interferon Alpha-2a in Virologically Suppressed Patients With Chronic Hepatitis B Virus Infection

  • Condition/Disease

    Virologically Suppressed Participants With Chronic Hepatitis B Virus Infection

  • Test Drug

    JNJ-73763989 JNJ-56136379 JNJ-56136379

Participate Sites
3Sites

Recruiting3Sites

2020-09-01 - 2024-07-05

Phase II

Completed
A Phase 2, Randomized, Open-label, Multicenter Study to Evaluate Efficacy, Pharmacokinetics, Safety, and Tolerability of Response-guided Treatment With JNJ-73763989 + JNJ-56136379 + Nucleos(t)Ide Analog Regimen With or Without Pegylated Interferon Alpha-2a in Treatment-naive Patients With HBeAg Positive Chronic Hepatitis B Virus Infection and Normal ALT

  • Condition/Disease

    HBeAg Positive Chronic Hepatitis B Virus Infection

  • Test Drug

    JNJ-56136379JNJ-73763989JNJ-56136379

Participate Sites
4Sites

Recruiting4Sites

2022-06-30 - 2024-05-31

Phase II

Completed

  • Condition/Disease

  • Test Drug

Participate Sites
4Sites

Terminated4Sites

2020-03-01 - 2024-03-31

Phase III

Completed

  • Condition/Disease

  • Test Drug

Participate Sites
6Sites

Terminated6Sites

2025-04-01 - 2030-06-18

Phase III

Active
A Phase III, Randomised, Open-Label, Sponsor-Blinded, Multicentre Study of Rilvegostomig in Combination with Bevacizumab with or without Tremelimumab as First-line Treatment in Patients With Advanced Hepatocellular Carcinoma (ARTEMIDE-HCC01)

  • Condition/Disease

    Advanced Hepatocellular Carcinoma

  • Test Drug

    Rilvegostomig (AZD2936) Tremelimumab BEVACIZUMAB

Participate Sites
8Sites

Recruiting8Sites

1 2 3 4 5 7
聯絡我們

台灣臨床試驗主持人資料庫 TPIDB

All Contents Copyright 2020 台灣臨床試驗主持人資料庫TPIDB